Actively Recruiting
Randomized Study of Osavampator as Add-On Therapy to Maintain Effect in Adults With Major Depressive Disorder
Led by Neurocrine Biosciences · Updated on 2026-10-22
550
Participants Needed
61
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness of osavampator compared to a placebo as an additional treatment to delay the return of depressive symptoms in adults with major depressive disorder MDD. This Phase 3 study focuses on maintaining treatment effects in participants diagnosed with recurrent moderate or severe MDD or persistent depressive disorder who have not responded adequately to oral antidepressants. The study aims to understand whether osavampator can help prevent relapse in this population. Participants will first receive osavampator during an initial open-label treatment phase. Following this, they will be randomly assigned to receive either osavampator or a matching placebo during a double-blind maintenance period. Both treatments are given as oral tablets, and participants will continue their existing oral antidepressants at the same dose and frequency throughout the study. The study may last up to approximately 32 months from randomization. During the study, participants will be regularly monitored for relapse of depressive symptoms using the Hamilton Depression Rating Scale. Researchers will track the time from randomization to relapse or the end of the study to assess treatment maintenance. Safety and adherence will be evaluated throughout, with participants expected to comply with study procedures and restrictions. The total duration of participation varies but can extend up to nearly three years.
CONDITIONS
Brief Title
A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Research Team
N
Neurocrine Medical Information Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here